• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
155471 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  / K9 \  x' i% R' Z5 _; r
/ S5 W4 m( e. A
9 ^; d- X! E1 a1 c$ W" t  F+ u- z
Sub-category:
/ c: Q8 x; o2 K5 nMolecular Targets
# k1 p* G, z" T, T4 j, T8 N) S! C4 C( Q$ e
1 t8 e* y6 h" O! W- N4 ]: U+ j: Y1 x
Category:
  [% }% |* z4 c3 R: B0 r! E# [0 z  JTumor Biology
; v+ R+ p* w) H0 l! d7 P) }1 h. \( h& z) q

# {2 J% [9 X7 @: U2 F' j9 W0 e8 ^& QMeeting:
; c* I4 L7 F( T9 [2011 ASCO Annual Meeting 9 A$ u1 H% s- s% A& D' a, m% m8 f% z* C" n
$ ]" D  _& B) a0 u
0 f2 m5 v5 l8 R2 m/ r5 G! E
Session Type and Session Title:
5 n/ A$ f, b9 I$ m( fPoster Discussion Session, Tumor Biology
1 c1 P- [- I! @5 A  s! b2 ]6 w" P
6 d0 f4 P& m; R2 G
Abstract No:4 K# }: a9 ?- I/ j
10517 2 S' z1 t# r- ^

: x, X4 C% x2 C; O9 S- ]( ~) Y* K2 Z' a$ \* y8 L) X2 {2 v
Citation:
) v9 D+ `5 z+ DJ Clin Oncol 29: 2011 (suppl; abstr 10517)
( b6 G& Z4 Q  S. A: ]* a
& ?' b/ M; S' |8 I$ u! Z; A6 l) X; u) t6 F# G$ ]9 G
Author(s):
) O) v4 l( }4 y" ^# `* WJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - E. V" A# }2 b& p/ S! }
. I' L# _; |/ j9 R) {' O9 \

$ l) u8 P" `4 w- |& Q* e
( T  T- d1 W( oAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
1 D# P# }( m. l8 ?! Q$ [8 r8 m2 P. k; K7 ?3 o8 ^' c' g% p* l
Abstract Disclosures
/ I* B5 ~$ I6 \7 g5 N. ~% p1 n- l( ]- H
Abstract:% f6 a4 v4 `9 a8 q9 W3 K) C: d
' \) H2 ], O0 f7 ]$ l

/ d! K# t3 [& c4 l5 D/ }* O2 QBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 B1 h6 H( ]  O) \8 |8 c$ f# C0 U/ }  H

/ Y% B2 t6 J) `& W4 v% b. l
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 " N' ]. B; c3 j% {7 A# M
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

) a" b/ O2 i/ B化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 # p; D4 {# [- f2 ^" |
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
8 b: P/ p8 {, i6 B" c$ SALK一个指标医院要900多 ...

6 ^9 q& v0 x7 O$ ]6 }7 w/ ^- t3 M& u1 Z平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
7 b8 J  Y( Q( D9 y8 E7 V- x6 d6 j+ y( C
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表